Study on the Role of Rebiopsy in Relapsed Non-Small Cell Lung Cancer for Directing Oncology Treatments

Background: In advanced non-small cell lung cancer relapses, few rebiopsies are being performed. They are not commonly used in lung cancer clinical practise. However, without identifying the type of new lesions, it is impossible to adequately target therapy in cases of relapse.

Clarify the existing situation and investigate the need for rebiopsy.

Design: This paper examines the existing literature on rebiopsy and addresses the significance of rebiopsy in advanced non-small cell lung cancer in general.

The information for further study consisted of 560 abstracts in total. Nineteen of the articles were regarding clinical rebiopsy in lung cancer and were thoroughly reviewed.

Conclusions: This review demonstrates that rebiopsy is possible in non-small cell lung cancer, and that success rates can be high if the procedure is preceded by thorough examination. Its application could help to overcome problems like sampling bias and detecting changes in cancer features. When treatment is chosen based on tissue features that change, the treatment selection procedure must be redone while taking into account new tumour characteristics. However, before rebiopsy, a thorough assessment of the risks of complications, including anatomic and technical elements of tumour access, should be carried out. Rebiopsy has the potential to forecast therapeutic resistance and, as a result, to refocus targeted medicines. Such knowledge could help tackle problems like sample bias, as well as selecting pre-existing clones and developing drug-resistant ones. In non-small cell lung cancer, rebiopsy should be done more frequently. After the first biopsy that established the diagnosis, a rebiopsy is performed.

Author(S) Details

Antti P. Jekunen
Clinical Cancer Research Center, Vaasa Oncology Clinic, Turku University, Hietalahdenkatu 2-4, Vaasa 65100, Finland.

View Book:-

Leave a Reply

Your email address will not be published. Required fields are marked *

Back To Top